openPR Logo
Press release

Monoclonal Antibodies-Global Trends in the Competitive, Technological and R&D Landscape

04-16-2018 07:53 PM CET | Health & Medicine

Press release from: ReportsWeb

Monoclonal Antibodies-Global Trends in the Competitive,

GBI Research's latest report, "Monoclonal Antibodies-Global Trends in the Competitive, Technological and R&D Landscape" discusses both the pipeline and market shares of monoclonal antibodies (mAbs) across a number of therapy areas. mAbs are defined as a collection of antibodies produced from a single B-cell clone. These antibodies therefore share binding specificity towards a certain antigen, and can be used as a means of targeted therapy within a number of indications across the pharmaceutical market.

mAbs have been in development in humans since the mid-1970s, and a substantial number of mAb products have entered the market. However, the majority are still in early-stage development, indicating delays and setbacks in the progression of potential products. Despite this, mAbs are the largest and fastest-growing segment of the biopharmaceutical sector, and account for almost half of the global revenue accrued from this area annually.

Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011199424/sample?utm_source=shekhar&utm_medium=op

The pipeline is highly active, with 2,836 mAbs currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. Additionally, there are currently 85 mAb programs in Phase III development, and 22 at the Pre-registration stage, accounting for just under 4% of the total mAb pipeline.

This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of mAbs, and assesses key developments in manufacturing and development, covering strategies to combat challenges associated with the use of mAbs in human patients.

Scope
-While many mAbs that enter the market achieve commercial success, a large proportion are stuck at early-stage development:
-What strategies can be put in place to advance the production of mAbs-
-What strategies can be used to improve both the affinity and therapeutic efficacy of mAbs-
-What are the relative advantages and disadvantages of each mAb type, and which hold the most promise-
-What proportion of the overall mAb R&D pipeline is occupied by each mAb type-
-In which therapy areas is there the highest level of R&D activity for mAbs-
-Which stage of development accounts for the majority of the pipeline-
-How do mAbs fit into the overall portfolios of companies developing them-
-What is the level of involvement in mAbs research for the top 15 Big Pharma companies-

Inquiry for Report@ http://www.reportsweb.com/inquiry&RW00011199424/buying?utm_source=shekhar&utm_medium=op

Key Reasons to Purchase
-Understand the current status of the field of therapeutic mAbs, and the relative clinical and commercial success of currently marketed products, comprising Humira, Remicade, Rituxan, Avastin, Herceptin, Opdivo, Lucentis, Stelara and Soliris
-Assess the pipeline for mAbs split by therapy area, mAb type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four most active therapy areas for mAbs: oncology, infectious diseases, immunology and central nervous system disorders
-Gain a picture of the current competitive landscape, with a detailed breakdown of the companies actively involved in the mAb pipeline. Understand the level of involvement of Big Pharma companies, and the extent to which mAbs fit into the portfolios of companies in this field. Additionally, a highly granular breakdown of companies developing mAbs is provided.

About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Monoclonal Antibodies-Global Trends in the Competitive, Technological and R&D Landscape here

News-ID: 1018600 • Views:

More Releases from ReportsWeb

North America: Smart Airport Market Overall Study Report 2020-2026| Amadeus IT Group S.A., Cisco, Honeywell, IBM, QinetiQ Group Plc, Sabre Corporation, Siemens ,Rockwell Collins Inc, Thales Group and T Systems International GmbH
North America: Smart Airport Market Overall Study Report 2020-2026| Amadeus IT G …
The "Global North America Smart Airport Market: 2020" Industry Report is a professional and in-depth study on the current state of the North America Smart Airport Market by PMR. The North America Smart Airport market is supposed to demonstrate a considerable growth during the forecast period of 2020 - 2026. The company profiles of all the key players and brands that are dominating the market have been given in this
Marine Biotechnology Market Future Forecast 2018-2026 by Leading Companies such as BASF, Abbott Laboratories, Lonza Group, Nofima, Aker Biomarine, Cyanotech Corporation, New England Biolabs, GlycoMar, Pharmamara, Nutrex Hawaii Incorporated, Marinova, Fmc
Marine Biotechnology Market Future Forecast 2018-2026 by Leading Companies such …
ReportsWeb.com has announced the addition of the “Marine Biotechnology-Global Market Outlook 2017-2026” The report classifies the global Marine Biotechnology Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. According to Publisher, the Global Marine Biotechnology Market is accounted for $3.93 billion in 2017 and is expected to reach $8.74 billion by 2026 growing at a CAGR of 9.3% during
Anti-Counterfeiting Packaging Market Growth Opportunities and Emerging Trends by Analysis of Key Vendors like Alien Technology, 3M Company, Acg Pharmapack, Advanced Track & Trace, AlpVision S.A., Angstrom Technologies, Atlantic Zeiser, TruTag Technologies
Anti-Counterfeiting Packaging Market Growth Opportunities and Emerging Trends by …
ReportsWeb.com has announced the addition of the “Anti-Counterfeiting Packaging-Global Market Outlook 2017-2026” The report classifies the global Anti-Counterfeiting Packaging Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. According to Publisher, the Global Anti-Counterfeiting Packaging Market is accounted for $112.16 billion in 2017 and is expected to reach $427.96 billion by 2026 growing at a CAGR of 16.0% during
Solar Photovoltaic in Italy Market Outlook to 2030 | Company Profiles (Tozzi Holding, Silver Ridge Power, RTR Capital, Mitsubishi Corporation, Etrion Corporation)
Solar Photovoltaic in Italy Market Outlook to 2030 | Company Profiles (Tozzi Hol …
Solar Photovoltaic (PV) in Italy, Market Outlook to 2030, Update 2018-Capacity, Generation, Investment Trends, Regulations and Company Profiles Summary "Solar Photovoltaic (PV) in Italy, Market Outlook to 2030, Update 2018-Capacity, Generation, Investment Trends, Regulations and Company Profiles", is the latest report from Publisher, the industry analysis specialists that offer comprehensive information and understanding of the Solar Photovoltaic (PV) market in Italy. The report provides in depth analysis on global renewable power market and

All 4 Releases


More Releases for Monoclonal

Impact COVID-19 on Monoclonal Antibodies Market 2021 Generated Opportunities for …
Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. For instance, in 2017,
Monoclonal Antibodies Market Outline and Updates..!!
Rising adoption of strategies such as acquisition, collaboration, and license agreement by the market players is expected to bolster the monoclonal antibodies market growth over the forecast period. For instance, in 2018, F. Hoffman-La Roche AG and Kymab Group Ltd entered into a clinical trial agreement to evaluate KY1044 (product of Kymab Group), a human monoclonal antibody, for the treatment of solid tumors. Also, in 2018, Novartis AG entered into
Global Monoclonal Antibody Diagnostic Reagents Market
Antibodies are an essential tool for many applications including flow cytometric analysis, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), immunocytochemistry, western blotting, and immunohistochemistry. Moreover, monoclonal antibodies (MAbs) are significant diagnostic reagent used in microbiological research, biomedical research, and also in diagnosis of various diseases such as HIV, hepatitis, herpes simplex, influenza infections, chlamydia, as well as for the treatment of cancer. Therefore, due to its importance in the clinical application, it
Monoclonal Antibody Custom Service Market Ravishing Growth with CAGR of 10.84% | …
Complete Study of Monoclonal Antibody Custom Service Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa. Avail Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4515 Monoclonal Antibody Custom Service Market – Overview It is estimated that monoclonal antibody custom service market is expected to
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future. There has been a
Global Cancer Monoclonal Antibodies Pipeline Analysis
In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies. In recent years the popularity